Screener
ImmunityBio, Inc. IBRX Reportable Segment — Other research and development costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept ibrx:ResearchAndDevelopmentExpenseInternalOtherCosts.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Internal research and development expense (including amounts with related parties): (2) | ||
| Personnel-related costs | 25,850 | 23,065 |
| Equipment, depreciation, and facility costs | 13,588 | 13,192 |
| Other research and development costs | 8,469 | 6,466 |
| Total internal research and development expense | 47,907 | 42,723 |
| Total research and development expense (including amounts with related parties) | 67,989 | 48,234 |
| Selling, general and administrative (including amounts with related parties) | 45,770 | 32,654 |
| Total operating expenses | 113,759 | 80,888 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s reportable segment — other research and development costs?
- ImmunityBio, Inc. (IBRX) reported reportable segment — other research and development costs of $8.47M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — other research and development costs changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — other research and development costs increased by 31.0% year-over-year, from $6.47M to $8.47M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — other research and development costs?
- Over 2 years (2023 to 2025), ImmunityBio, Inc.'s reportable segment — other research and development costs has grown at a 32.0% compound annual growth rate (CAGR), from $24.35M to $42.43M.
- What does reportable segment — other research and development costs mean?
- Encompasses miscellaneous research and development expenses not categorized as internal personnel or external contract costs. This may include laboratory supplies, software licenses, and regulatory filing fees.
Ask your AI about ImmunityBio, Inc.'s reportable segment — other research and development costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude